An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies.

Trial Profile

An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Afuresertib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 15 Sep 2017 Planned End Date changed from 18 Dec 2017 to 18 Apr 2018.
    • 15 Sep 2017 Planned primary completion date changed from 18 Dec 2017 to 18 Apr 2018.
    • 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top